Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 4.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,131,628 shares of the biopharmaceutical company’s stock after purchasing an additional 130,025 shares during the period. Charles Schwab Investment Management Inc. owned 0.53% of Royalty Pharma worth $79,888,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of RPRX. Swedbank AB lifted its stake in Royalty Pharma by 10.3% in the fourth quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company’s stock worth $310,308,000 after acquiring an additional 1,136,800 shares during the last quarter. Two Sigma Advisers LP lifted its stake in Royalty Pharma by 44.7% in the third quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company’s stock worth $85,809,000 after acquiring an additional 936,900 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in Royalty Pharma in the third quarter worth approximately $14,898,000. Geode Capital Management LLC lifted its stake in Royalty Pharma by 6.1% in the third quarter. Geode Capital Management LLC now owns 7,265,786 shares of the biopharmaceutical company’s stock worth $205,562,000 after acquiring an additional 417,490 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in Royalty Pharma by 303.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 539,995 shares of the biopharmaceutical company’s stock worth $13,926,000 after acquiring an additional 406,123 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, TD Cowen upgraded shares of Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $41.60.

Royalty Pharma Stock Down 0.8 %

RPRX stock opened at $32.75 on Tuesday. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. Royalty Pharma plc has a twelve month low of $24.05 and a twelve month high of $34.20. The company’s 50 day moving average is $31.02 and its two-hundred day moving average is $28.44. The stock has a market cap of $18.88 billion, a P/E ratio of 22.59, a PEG ratio of 2.31 and a beta of 0.47.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Research analysts expect that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 10th. Stockholders of record on Friday, February 21st were issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.69%. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date was Friday, February 21st. Royalty Pharma’s payout ratio is presently 60.69%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.